ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Omega-3 Polyunsaturated Fatty Acids Effect on Neuropathy of the Peripheral Nervous System in Dietary Obese Rats: Is the Source of These Fatty Acids Important for Outcome?
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dietary monounsaturated fatty acids reduce nerve inflammation and improve nerve function in murine models of obesity.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Objective: To answer the question what is the best source or composition of omega-3 polyunsaturated fatty acids (PUFA) that will provide the most favorable and safe outcome for peripheral neuropathy (PN) in an animal model of obesity? Traditionally encapsulated fish oil is the primary source of omega-3 PUFA as a nutritional supplement. However, other sources exist that could be a better environmental, safety, and/or economic choice. Methods: Male Sprague Dawley rats 12 weeks of age were fed a 45% kcal diet to induce obesity and model pre-diabetes. Early and late intervention protocols were used to determine the ability of omega-3 PUFA derived from menhaden (fish) oil, krill oil, algal oils, or ethyl esters to slow the progression or reverse PN associated with pre-diabetes by examining multiple endpoints of sensory nerve function, morphometry and vascular reactivity. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the primary omega-3 PUFA, and a combination exist in fish and krill oil. However, algal oils and ethyl esters are available as EPA, DHA, or EPA & DHA and each were used in this study. Results: We report that multiple sources of omega-3 PUFA are a proactive treatment for PN that occurs with pre-diabetes including improvement in sensory nerve conduction velocity, thermal nociception and cornea sensitivity and corneal nerve fiber length. Improvement in vascular reactivity of epineurial arterioles of the sciatic nerve was observed. We also report that EPA and DHA had different outcomes for these endpoints. Conclusion: We confirm that omega-3 PUFA are an effective treatment to prevent and reverse PN associated with obesity and pre-diabetes. Additional studies will be needed to definitively determine what would be the best and most consistent source of this important nutritional supplement from an environmental and economical viewpoint.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.